These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 6765062)
41. Bromocriptine (ParlodelR) in the treatment of Parkinson's disease. Molina-Negro P; Grimes JD; Jones MW; Kofman OS; Bouchard S Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):503-8. PubMed ID: 6761765 [No Abstract] [Full Text] [Related]
42. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms]. Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD Therapie; 1993; 48(3):233-8. PubMed ID: 7908147 [TBL] [Abstract][Full Text] [Related]
43. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease. Anglès A; Bagheri H; Saivin S; Montastruc JL Therapie; 2002; 57(4):408-10. PubMed ID: 12422563 [No Abstract] [Full Text] [Related]
44. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis. Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626 [TBL] [Abstract][Full Text] [Related]
45. [Use of bromocriptine in Parkinson diseases in low doses at a slow rate. 40 patients]. Liaño H; López-Lozano JJ; Ramírez A; Rabes C; Pascual ML Arch Neurobiol (Madr); 1984; 47(3):143-50. PubMed ID: 6508478 [No Abstract] [Full Text] [Related]
46. Dystonia: treatment with bromocriptine. Newman RP; LeWitt PA; Shults C; Bruno G; Foster NL; Chase TN; Calne DB Clin Neuropharmacol; 1985; 8(4):328-33. PubMed ID: 3907823 [TBL] [Abstract][Full Text] [Related]
47. A multi-center, double-blind study on slow-release bromocriptine in the treatment of Parkinson's disease. Mannen T; Mizuno Y; Iwata M; Goto I; Kanazawa I; Kowa H; Nishitani H; Ogawa N; Takahashi A; Tashiro K Neurology; 1991 Oct; 41(10):1598-602. PubMed ID: 1922801 [TBL] [Abstract][Full Text] [Related]
48. [Therapeutic effects of Nicholin (CDP-choline): Parkinson's syndrome.--a double-blind study]. Tsubaki T; Kase M; Ando K; Manaka N; Sato Y Nihon Rinsho; 1974 Nov; 32(11):3435-50. PubMed ID: 4616105 [No Abstract] [Full Text] [Related]
49. A double-blind evaluation of lysivane in the treatment of Parkinson's disease. Strang RR Br J Clin Pract; 1966 May; 20(5):249-51. PubMed ID: 5326485 [No Abstract] [Full Text] [Related]
50. Clinical evaluation of biperiden in Parkinson's disease. Strang RR Dis Nerv Syst; 1967 Mar; 28(3):191-3. PubMed ID: 5335879 [No Abstract] [Full Text] [Related]
52. A double-blind evaluation of S.D. 25 in the treatment of Parkinson's disease. Strang RR Curr Med Drugs; 1966 Dec; 7(4):20-6. PubMed ID: 5976205 [No Abstract] [Full Text] [Related]
53. Cognitive performances in parkinsonians before and after bromocriptine therapy. Piccirilli M; Piccinin GL; D'Alessandro P; Finali G; Piccolini C; Scarcella MG; Testa A Acta Neurol (Napoli); 1986 Jun; 8(3):167-72. PubMed ID: 3739763 [No Abstract] [Full Text] [Related]